All Stories

  1. T cell tolerant fraction as a predictor of graft-vs-host disease following allogeneic hematopoietic cell transplantation

    Article • November 2025, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  2. Understanding Telomere Biology in Hematopoietic Cell Transplantation: A Dynamical Systems Perspective

    Article • Transplantation and Cellular Therapy, July 2025, Elsevier

    Dr Amir Ahmed Toor

  3. Understanding Telomere Biology in Hematopoietic Cell Transplantation: A Dynamical Systems Perspective

    Article • January 2025, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  4. Differential Antibody Response To Polysaccharide Vaccines Following Allogeneic Stem Cell Transplantation; A Dynamical Systems Perspective

    Article • July 2024, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  5. Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA‐matched unrelated donor HCT in paediatric acute leukaemia

    Article • British Journal of Haematology, March 2024, Wiley

    Dr Amir Ahmed Toor

  6. Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee

    Article • Transplantation and Cellular Therapy, March 2024, Elsevier

    Dr Amir Ahmed Toor

  7. Increased Donor Inhibitory KIR Are Associated with Reduced GVHD and Improved Survival Following HLA Matched Unrelated Donor HCT in Pediatric Acute Leukemia

    Article • December 2023, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  8. INTRAVENOUS VITAMIN C SUPPLEMENTATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: SALUTARY IMPACT ON CLINICAL OUTCOMES

    Article • October 2023, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  9. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

    Article • EClinicalMedicine, May 2023, Elsevier

    Dr Amir Ahmed Toor

  10. Cell‐free next‐generation sequencing impacts diagnosis and antimicrobial therapy in immunocompromised hosts: A retrospective study

    Article • Transplant Infectious Disease, January 2023, Wiley

    Dr Amir Ahmed Toor

  11. Allogeneic haematopoietic cell transplants as dynamical systems: influence of early‐term immune milieu on long‐term T‐cell recovery

    Article • Clinical & Translational Immunology, January 2023, Wiley

    Dr Amir Ahmed Toor

  12. DNA Methylation Changes in Autologous Hematopoietic Stem Cell Transplant Patients

    Article • Biological Research For Nursing, November 2022, SAGE Publications

    Dr Amir Ahmed Toor

  13. Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis

    Article • British Journal of Pharmacology, October 2022, Springer Science + Business Media

    Dr Amir Ahmed Toor

  14. Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Antithymocyte Globulin Administration Schedules in Allogeneic Stem Cell Transplantation

    Article • Transplantation and Cellular Therapy, February 2022, Elsevier

    Dr Amir Ahmed Toor

  15. Transient left ventricular dysfunction following chimeric antigen receptor T‐cell‐mediated encephalopathy: A form of stress cardiomyopathy

    Article • eJHaem, December 2021, Wiley

    Dr Amir Ahmed Toor

  16. High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation

    Article • Journal of Oncology Pharmacy Practice, December 2021, SAGE Publications

    Dr Amir Ahmed Toor

  17. Correction: Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML

    Article • British Journal of Pharmacology, October 2021, Springer Science + Business Media

    Dr Amir Ahmed Toor

  18. Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia

    Article • Clinical Case Reports, October 2021, Wiley

    Dr Amir Ahmed Toor

  19. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML

    Article • British Journal of Pharmacology, July 2021, Springer Science + Business Media

    Dr Amir Ahmed Toor

  20. What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?

    Article • eJHaem, May 2021, Wiley

    Dr Amir Ahmed Toor

  21. On the Order of Gene Distribution on Chromosomes Across the Animal Kingdom

    Article • December 2019, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  22. Reduced plasma ascorbic acid levels in recipients of myeloablative conditioning and hematopoietic cell transplantation

    Article • European Journal Of Haematology, August 2019, Wiley

    Dr Amir Ahmed Toor

  23. Hematopoietic stem cell mobilization following PD‐1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid

    Article • European Journal Of Haematology, June 2019, Wiley

    Dr Amir Ahmed Toor

  24. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy

    Article • Leukemia & Lymphoma, May 2019, Taylor & Francis

    Kelly Hawks, Dr Amir Ahmed Toor

  25. Are We Overlooking the Use of Oral Ribavirin for Respiratory Syncytial Virus Infection Following Hematopoietic Stem Cell Transplantation?

    Article • Current Treatment Options in Infectious Diseases, May 2019, Springer Science + Business Media

    Dr Amir Ahmed Toor

  26. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies

    Article • Leukemia & Lymphoma, April 2018, Taylor & Francis

    Dr Amir Ahmed Toor, Kelly Hawks

  27. The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation

    Article • Leukemia & Lymphoma, April 2018, Taylor & Francis

    Dr Amir Ahmed Toor

  28. Reconstituting donor T cells increase their biomass following hematopoietic stem cell transplantation

    Article • The Analyst, January 2018, Royal Society of Chemistry

    Dr Amir Ahmed Toor

  29. Conditioning neoadjuvant therapies for improved immunotherapy of cancer

    Article • Biochemical Pharmacology, December 2017, Elsevier

    Dr Amir Ahmed Toor

  30. Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation

    Article • PLOS One, December 2017, PLOS

    Dr Amir Ahmed Toor

  31. DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle

    Article • Nature Communications, November 2017, Springer Science + Business Media

    Dr Amir Ahmed Toor

  32. Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivity

    Article • PLOS One, August 2017, PLOS

    Dr Amir Ahmed Toor

  33. Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis

    Article • Leukemia & Lymphoma, May 2017, Taylor & Francis

    Dr Amir Ahmed Toor

  34. Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model

    Article • The Prostate, November 2016, Wiley

    Dr Amir Ahmed Toor

  35. Treatment of acute fibrinous organizing pneumonia following hematopoietic cell transplantation with etanercept

    Article • British Journal of Pharmacology, August 2016, Springer Science + Business Media

    Dr Amir Ahmed Toor

  36. The Influence of Lymphoid Reconstitution Kinetics on Clinical Outcomes in Allogeneic Stem Cell Transplantation

    Article • July 2016, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  37. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor–Recipient Pairs

    Article • Biology of Blood and Marrow Transplantation, May 2016, Elsevier

    Dr Amir Ahmed Toor

  38. Stem Cell Transplantation as a Shattering Event: Meaning Making, Coping and Adjustment

    Article • Biology of Blood and Marrow Transplantation, March 2016, Elsevier

    Dr Amir Ahmed Toor

  39. Enhanced Immunosuppression Free Survival in Matched Related Donor Hematopoietic Cell Transplant Recipients Conditioned with Anti-Thymocyte Globulin

    Article • Biology of Blood and Marrow Transplantation, March 2016, Elsevier

    Dr Amir Ahmed Toor

  40. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells

    Article • Journal of Leukocyte Biology, February 2016, Oxford University Press (OUP)

    Dr Amir Ahmed Toor

  41. On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments

    Article • Journal of The Royal Society Interface, January 2016, Royal Society Publishing

    Dr Amir Ahmed Toor

  42. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential In HLA-Matched and Mismatched Donor-Recipient Pairs

    Article • August 2015, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  43. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes

    Article • Biology of Blood and Marrow Transplantation, July 2015, Elsevier

    Dr Amir Ahmed Toor

  44. Dynamical System Modeling of Immune Reconstitution Following Allogeneic Stem Cell Transplantation (SCT) Conditioned with Rabbit Anti-Thymocyte Globulin

    Article • Biology of Blood and Marrow Transplantation, February 2015, Elsevier

    Dr Amir Ahmed Toor

  45. On The Organization Of Human T Cell Receptor Loci.

    Article • January 2015, Cold Spring Harbor Laboratory Press

    Dr Amir Ahmed Toor

  46. Stem Cell Transplantation as a Dynamical System: Are Clinical Outcomes Deterministic?

    Article • Frontiers in Immunology, December 2014, Frontiers

    Dr Amir Ahmed Toor

  47. In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation

    Article • Frontiers in Immunology, November 2014, Frontiers

    Dr Amir Ahmed Toor

  48. Etiology of GVHD: Alloreactivity or Impaired Cellular Adaptation?

    Article • Immunological Investigations, October 2014, Taylor & Francis

    Dr Amir Ahmed Toor

  49. Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation

    Article • British Journal of Haematology, April 2014, Wiley

    Dr Amir Ahmed Toor

  50. In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donor-Recipient Pairs

    Article • Biology of Blood and Marrow Transplantation, February 2014, Elsevier

    Dr Amir Ahmed Toor

  51. On The Organization Of Human T Cell Receptor Loci

    Article • Blood, November 2013, American Society of Hematology

    Dr Amir Ahmed Toor

  52. Fractal Organization of the Human T Cell Repertoire in Health and after Stem Cell Transplantation

    Article • Biology of Blood and Marrow Transplantation, March 2013, Elsevier

    Dr Amir Ahmed Toor

  53. An Outcome-Adaptive Allocation Method for Clinical Trials With Dual Binary Objectives

    Article • Statistics in Biopharmaceutical Research, February 2013, Taylor & Francis

    Dr Amir Ahmed Toor

  54. Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity

    Article • British Journal of Haematology, July 2012, Wiley

    Dr Amir Ahmed Toor

  55. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients

    Article • British Journal of Pharmacology, May 2012, Springer Science + Business Media

    Dr Amir Ahmed Toor

  56. Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation

    Article • Biology of Blood and Marrow Transplantation, May 2012, Elsevier

    Dr Amir Ahmed Toor

  57. Distinct Oligoclonal T Cells Are Associated With Graft Versus Host Disease After Stem-Cell Transplantation

    Article • Transplantation, May 2012, Wolters Kluwer Health

    Dr Amir Ahmed Toor

  58. Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk

    Article • Clinical and Developmental Immunology, January 2012, Hindawi Publishing Corporation

    Dr Amir Ahmed Toor

  59. Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse

    Article • The Journal of Immunology, July 2011, The American Association of Immunologists

    Dr Amir Ahmed Toor

  60. Comment on “Cutting Edge: CD8+ T Cell Priming in the Absence of NK Cells Leads to Enhanced Memory Responses”

    Article • The Journal of Immunology, June 2011, The American Association of Immunologists

    Dr Amir Ahmed Toor

  61. Distinct Oligoclonal T Cells Are Associated With GVHD or GVHD-Free Responses in Patients With Hematologic Malignancies Following Stem Cell Transplantation

    Article • Biology of Blood and Marrow Transplantation, February 2011, Elsevier

    Dr Amir Ahmed Toor

  62. <em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

    Article • Journal of Visualized Experiments, January 2011, MyJove Corporation

    Dr Amir Ahmed Toor

  63. Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation

    Article • Biology of Blood and Marrow Transplantation, May 2010, Elsevier

    Dr Amir Ahmed Toor

  64. Rearrangements of theMLLgene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding

    Article • Genes Chromosomes and Cancer, September 2009, Wiley

    Dr Amir Ahmed Toor

  65. Dose intense therapy for relapsed lymphoproliferative disorders: the more things change, the more they are the same

    Article • Leukemia & Lymphoma, January 2009, Taylor & Francis

    Dr Amir Ahmed Toor

  66. Impaired NHEJ function in multiple myeloma

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, January 2009, Elsevier

    Dr Amir Ahmed Toor

  67. Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT

    Article • British Journal of Pharmacology, August 2008, Nature

    Dr Amir Ahmed Toor

  68. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections

    Article • Transplant Infectious Disease, June 2007, Wiley

    Dr Amir Ahmed Toor

  69. Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma

    Article • Biology of Blood and Marrow Transplantation, May 2007, Elsevier

    Dr Amir Ahmed Toor

  70. Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity

    Article • Journal of Dermatological Treatment, January 2007, Taylor & Francis

    Dr Amir Ahmed Toor

  71. Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis

    Article • British Journal of Pharmacology, October 2006, Springer Science + Business Media

    Dr Amir Ahmed Toor

  72. Cardiac nonamyloidotic immunoglobulin deposition disease

    Article • Modern Pathology, February 2006, Elsevier

    Dr Amir Ahmed Toor

  73. Patients' understanding of disease status and treatment plan at initial hematopoietic stem cell transplantation consultation

    Article • British Journal of Pharmacology, January 2006, Springer Science + Business Media

    Dr Amir Ahmed Toor

  74. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma

    Article • Leukemia & Lymphoma, January 2006, Taylor & Francis

    Dr Amir Ahmed Toor

  75. The Administration of Polymerized Human Hemoglobin (Pyridoxylated) to a Jehovah's Witness After Submyeloablative Stem Cell Transplantation Complicated by Delayed Graft Failure

    Article • Comprehensive Therapy, January 2006, Springer Science + Business Media

    Dr Amir Ahmed Toor

  76. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines

    Article • Blood, December 2004, American Society of Hematology

    Dr Amir Ahmed Toor

  77. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor

    Article • British Journal of Pharmacology, November 2004, Springer Science + Business Media

    Dr Amir Ahmed Toor

  78. Post-transplant air-leak syndrome

    Article • British Journal of Haematology, July 2004, Wiley

    Dr Amir Ahmed Toor

  79. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma

    Article • British Journal of Haematology, February 2004, Wiley

    Dr Amir Ahmed Toor

  80. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective

    Article • Biology of Blood and Marrow Transplantation, March 2003, Elsevier

    Dr Amir Ahmed Toor

  81. Infection - an underappreciated cause of bone pain in multiple myeloma

    Article • British Journal of Haematology, March 2003, Wiley

    Dr Amir Ahmed Toor

  82. Clinical activity of arsenic trioxide for the treatment of multiple myeloma

    Article • Leukemia, August 2002, Springer Science + Business Media

    Dr Amir Ahmed Toor

  83. Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications

    Article • Blood Coagulation & Fibrinolysis, April 2002, Wolters Kluwer Health

    Dr Amir Ahmed Toor

  84. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

    Article • British Journal of Haematology, March 2002, Wiley

    Dr Amir Ahmed Toor

  85. Acquired factor VII deficiency in hematopoietic stem cell transplant recipients

    Article • British Journal of Pharmacology, March 2002, Springer Science + Business Media

    Dr Amir Ahmed Toor

  86. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning

    Article • Transfusion, February 2002, Wiley

    Dr Amir Ahmed Toor

  87. Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

    Article • British Journal of Haematology, January 2002, Wiley

    Dr Amir Ahmed Toor

  88. Infections during mobilizing chemotherapy and following autologous stem cell transplantation

    Article • British Journal of Pharmacology, December 2001, Springer Science + Business Media

    Dr Amir Ahmed Toor

  89. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy

    Article • Blood, September 2001, American Society of Hematology

    Dr Amir Ahmed Toor

  90. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

    Article • Blood, May 2001, American Society of Hematology

    Dr Amir Ahmed Toor

  91. T-cell factor-1 expression during human natural killer cell development and in circulating CD56+ bright natural killer cells

    Article • Experimental Hematology, April 2001, Elsevier

    Dr Amir Ahmed Toor

  92. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone

    Article • British Journal of Haematology, January 2001, Wiley

    Dr Amir Ahmed Toor